Hypothalamic obesity: Epidemiology in rare sellar/suprasellar tumors-A German claims database analysis.
craniopharyngioma
endocrinology
hypothalamic obesity
rare sellar/suprasellar tumors
tumor/treatment related HO
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
05
06
2024
received:
15
03
2024
accepted:
29
07
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Hypothalamic obesity (HO) is defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment-related damage to the hypothalamus. HO epidemiology is poorly understood. We developed a database algorithm supporting the standardized identification of tumor/treatment-related HO (TTR-HO) patients. The algorithm is used to estimate incidence rates of TTR-HO patients in the German healthcare context from a representative claims database (n = 5.42 million) covering 2010-2020. Patients were identified based on surgery/radiotherapy procedures and HO-associated tumor diagnoses (n = 3976). HO was defined by incident obesity and validated based on incident diabetes insipidus diagnoses and desmopressin prescription within a 12-month period after surgery/radiotherapy. Uncertainty due to algorithm definitions is explored in sensitivity analyses. Estimated annual incidence of TTR-HO in Germany is between 0.7 and 1.7 cases per 1,000,000 persons (2019 prevalence: n = 1262 patients). With observed cases in all age groups, two HO-incidence peaks are identified: children/young adults aged 10-24 years and adults aged 40-44 years. Most frequent HO-validated tumor diagnoses are benign sellar/suprasellar tumors (6.1/1,000,000 persons over 9 years), including tumors of the craniopharyngeal duct (1.3/1,000,000), neoplasms of the pituitary gland (4.1/1,000,000), and nonspecific brain tumors of endocrine glands (2.4/1,000,000). This is the first real-world database analysis of TTR-HO epidemiology, refining current estimates of HO epidemiology and early patient identification. A more comprehensive characterization of patients with HO as well as a better understanding of clinical implications will be crucial in developing optimal treatment strategies to improve patient outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13439Subventions
Organisme : Rhythm Pharmaceuticals, Inc.
Informations de copyright
© 2024 The Author(s). Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Références
Müller HL, Merchant TE, Warmuth‐Metz M, Martinez‐Barbera J‐P, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. doi:10.1038/s41572‐019‐0125‐9
Müller HL. Craniopharyngioma. Handb Clin Neurol. 2014;124:235‐253. doi:10.1016/B978‐0‐444‐59602‐4.00016‐2
Abuzzahab MJ, Roth CL, Shoemaker AH. Hypothalamic obesity: prologue and promise. Horm Res Paediatr. 2019;91(2):128‐136. doi:10.1159/000496564
Feola T, Pirchio RS, Puliani G, et al. Sellar and parasellar lesions in the transition age: a retrospective Italian multi‐+ study. J Endocrinol Invest. 2023;46(1):181‐188. doi:10.1007/s40618‐022‐01900‐9
Daousi C, MacFarlane IA, English PJ, et al. Is there a role for ghrelin and peptide‐YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? J Clin Endocrinol Metab. 2005;90(9):5025‐5030. doi:10.1210/jc.2004‐1874
Müller HL, Tauber M, Lawson EA, et al. Hypothalamic syndrome. Nat Rev Dis Primers. 2022;8(1):24. doi:10.1038/s41572‐022‐00351‐z
Roth CL, Eslamy H, Werny D, et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity (Silver Spring). 2015;23(6):1226‐1233. doi:10.1002/oby.21067
Müller HL. Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab. 2011;96(7):1981‐1991. doi:10.1210/jc.2011‐0174
Müller HL, Emser A, Faldum A, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89(7):3298‐3305. doi:10.1210/jc.2003‐031751
Müller HL, Gebhardt U, Faldum A, et al. Functional capacity and body mass index in patients with sellar masses—cross‐sectional study on 403 patients diagnosed during childhood and adolescence. Childs Nerv Syst. 2005;21(7):539‐545. doi:10.1007/s00381‐005‐1166‐9
Müller HL. Management of hypothalamic obesity. Endocrinol Metab Clin North Am. 2020;49(3):533‐552. doi:10.1016/j.ecl.2020.05.009
Steele CA, Cuthbertson DJ, MacFarlane IA, et al. Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. Eur J Endocrinol. 2013;168(4):501‐507. doi:10.1530/EJE‐12‐0792
Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth‐Metz M, Daubenbüchel AMM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood‐onset craniopharyngioma: newly reported long‐term outcomes. Neuro Oncol. 2015;17(7):1029‐1038. doi:10.1093/neuonc/nov044
Deepak D, Furlong NJ, Wilding JPH, MacFarlane IA. Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic‐pituitary disease. Postgrad Med J. 2007;83(978):277‐280. doi:10.1136/pgmj.2006.052241
Haliloglu B, Atay Z, Guran T, et al. Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours. Pediatr Obes. 2016;11(5):383‐388. doi:10.1111/ijpo.12076
Rose SR, Horne VE, Bingham N, Jenkins T, Black J, Inge T. Hypothalamic obesity: 4 years of the international registry of hypothalamic obesity disorders. Obesity (Silver Spring). 2018;26(11):1727‐1732. doi:10.1002/oby.22315
Busse R, Blümel M, Knieps F, Bärnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self‐governance, and competition. Lancet. 2017;390(10097):882‐897. doi:10.1016/S0140‐6736(17)31280‐1
Bundesministerium für Gesundheit. Mitglieder und Versicherte der Gesetzlichen Krankenversicherung (GKV): Statistik uber Versicherte, gegliedert nach Status, Alter, Wohnort und Kassenart; 2020. Accessed December 12, 2023. https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/mitglieder-und-versicherte
Swart E, Gothe H, Geyer S, et al. Gute Praxis Sekundärdatenanalyse (GPS): Leitlinien und Empfehlungen. Gesundheitswesen. 2015;77(2):120‐126. doi:10.1055/s‐0034‐1396815
Kim JH, Choi J‐H. Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann Pediatr Endocrinol Metab. 2013;18(4):161‐167. doi:10.6065/apem.2013.18.4.161
Hochberg I, Hochberg Z. Expanding the definition of hypothalamic obesity. Obes Rev. 2010;11(10):709‐721. doi:10.1111/j.1467‐789X.2010.00727.x
Ghaferi AA, Schwartz TA, Pawlik TM. STROBE reporting guidelines for observational studies. JAMA Surg. 2021;156(6):577‐578. doi:10.1001/jamasurg.2021.0528
Bunin GR, Surawicz TS, Witman PA, Preston‐Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89(4):547‐551. doi:10.3171/jns.1998.89.4.0547
Dogra P, Bedatsova L, van Gompel JJ, Giannini C, Donegan DM, Erickson D. Long‐term outcomes in patients with adult‐onset craniopharyngioma. Endocrine. 2022;78(1):123‐134. doi:10.1007/s12020‐022‐03134‐4
Roth CL. Hypothalamic obesity in Craniopharyngioma patients: disturbed energy homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. J Clin Med. 2015;4(9):1774‐1797. doi:10.3390/jcm4091774
Seckl JR, Dunger DB. Diabetes insipidus. Current treatment recommendations. Drugs. 1992;44(2):216‐224. doi:10.2165/00003495‐199244020‐00006
Shoemaker AH, Tamaroff J. Approach to the patient with hypothalamic obesity. J Clin Endocrinol Metab. 2023;108(5):1236‐1242. doi:10.1210/clinem/dgac678
Dimitri P. Treatment of acquired hypothalamic obesity: now and the future. Front Endocrinol (Lausanne). 2022;13:846880. doi:10.3389/fendo.2022.846880
Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open‐label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):P380‐389. doi:10.1016/S2213‐8587(24)00087‐1
Reber KC, Angelow A, Schmidt CO, Baumeister S, Chenot J‐F. Externe Diagnosevalidierung von Routinedaten am Beispiel ausgewählter kardiovaskulärer Risikofaktoren. German Medical Science GMS Publishing House; 2015.
Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data analyses in Germany—a systematic review. Health Policy. 2016;120(2):213‐226. doi:10.1016/j.healthpol.2016.01.007